Member Info for Dicko80

It seems to be poised , whoever is controlling the bid and buy price ticking up now 0.0687

Was hoping for a few more in 0.050s

“Painful journey via Brussels and Luanda to Kinshasa. But seeing the gold price cheers me up no end as I sit on the tarmac in Angola.....“

Sale of gold asset ?

Gold production ?

New gold project ?

21-Jan-25 10:54:50 2.94 510,017 Unknown* 14.99k O

Big buy filled this morning, didn’t print though till late

Was 2.6 - 2.8 at the time

Then dropped it throughout day for cheap shares to fill that order

Hi Dansey

No nothing to do with me, just an observation from a chart point of view

6 months of sideways movement , now looking to breakout and start an uptrend

Thank you for your kind words

But clearly , one cannot read

Https://x.com/darrenukdaytra1/status/1881297773397766160?s=46

Https://x.com/abell2019/status/1881316584062599322?s=46

Go on Andrew 👏👏👏👏

Remember it’s just the start

Expect more deals

Reminds me of ONDO 5p to 40p+

Yes playing a game at the minute

Expect a tick up when they’re happy

I’m expecting an update as per the company’s LinkedIn post

Chart is suggesting a breakout from the 6months sideways movement and start of an uptrend

Someone wants in today

In auction

0.07 - 0.07

It’s all about timing

TRLS was 40p at IPO, I bought at 0.62p the day before it went up 750%

TRP once had a valuation of £400m, I was buying at 0.012 at. Under £2m mkt cap, re rated to 0.055 recently

Both examples are when “commercial negotiations “ have been in place

Who else do we know in commercial negotiations ?

Https://nuformix.com/app/uploads/2021/06/Allenby-Initiation-Note-March-2021.pdf

Page 29 valuation

Bottom paragraph

global sales deal $360 - 450m

Remember 2 or 3 years ago, the ballpark sum quoted for global sales deal for NPX002 based on $1bn sales per annum was $360- $450 m

So for NPX004 potentially $10bn sales per year by 2028 , well do the math on the potential deal using NPX002 numbers

Mkt cap £0.7m

Yes in this sector it’s the time it takes to get to commercial discussions stage, timeframe of years of R&D, to proof of concept, to obtaining patents, to maximise reach and worldwide global status , it’s now that time for NPX002

NPX004 really can’t see it going anywhere other than AZ , commercial discussions ongoing with parties they have to be one and you would expect they could announce an agreement at any time or face losing it to someone else

Let’s just be straight …

$10bn sales by 2028 for their lynparza

little old NFX NPX004 out performs Lynparza

current mkt cap just £700k

Make no bones about it ..

AZ will not let NPX004 go anywhere else

The Company's NXP004 programme is focused on the development of novel, proprietary, cocrystal forms of olaparib, a drug currently marketed by AstraZeneca, under the Lynparza® brand name.

On 14 June 2024 the US Patent and Trademark Office ("PTO") has granted the Company patent number 12012386 covering the lead cocrystals under development, representing the first granted patent in this second NXP004 cocrystal series.

Dr Dan Gooding, Executive Director of Nuformix, said: "I'm delighted we've received these multiple grants of key patents underpinning both our NXP002 and NXP004 programmes. The European patent grant represents the last major territory to confirm protection of the novel drug forms enabling NXP002's development as a potential novel IPF treatment. Granting of the method of use patent in the US further strengthens our IP position for this programme. The US PTO's decision to grant the patent protecting the NXP004 programme's lead cocrystals is also a first, with other territories soon to follow. The granting of these patents is very helpful and timely in progressing on-going discussions with potential development partners."

June 2024

Dr Dan Gooding, Executive Director of Nuformix, said: "Our research efforts and external discussions to date demonstrate that inhaled treatment of IPF and related fibrotic lung diseases via NXP002 is a viable and attractive concept. We remain focused on generating data and initiating, and further developing, discussions with potential partners that will support our efforts to secure out-license deals on NXP002 and NXP004. Progression of these opportunities is being achieved using existing funds thanks to a lean operational model, which will continue to operate until our R&D and targeted partnering activities require further resource. I am excited by our prospects for the remainder of the year and look forward to sharing results as they emerge."

Mkt cap 700k

IPO £12m

NPX004 potential blockbuster annual sales

Expect more patents in the short term

Commercial discussions with multiple potential partners

NPX004 - blockbuster potential

The Group discovered novel forms of olaparib, a drug currently marketed by AstraZeneca, as Lynparza®. Lynparza® was first approved in December 2014 for the treatment of adults with advanced ovarian cancer and deleterious or suspected deleterious germline BRCA mutation. Since then, it has secured similar approvals in breast, pancreatic and prostate cancers with further trials on-going.

These approvals have propelled Lynparza® sales to US$2.6bn in 2022 with industry analysts forecasting annual sales of US$9.7bn by 2028.

Subsequently, further preformulation and in-vitro studies allowed Nuformix to identify lead cocrystals to be progressed for further development.

Results from in vitro dissolution studies demonstrated that the two lead NXP004 cocrystals OUT PERFORMED Lynparza®, both in terms of rate and extent of dissolution and release of olaparib.

Enhancement of dissolution in the currently marketed formulation of Lynparza® resulted in improved bioavailability versus the initial marketed product.

Therefore, NXP004 may offer potential to further increase olaparib's bioavailability. In addition, the potential simplicity of NXP004-based formulations may offer improvements in product cost-of-goods versus the currently marketed product, which requires complex manufacturing methods.

These attributes position NXP004 for applications in line-extensions for the currently marketed product, or for possible development in future first-to-generic product opportunities.This work will direct and support future out-licensing discussions for NXP004.

This raises the possibility that NXP002 targets additional disease pathways to SoC's when increasing the combined anti-fibrotic and anti-inflammatory response. Following success in suppressing biomarkers of fibrotic disease progression in human IPF lung tissue, the same samples were analysed to assess additional mechanistic and anti-inflammatory benefits on top of SoC's and the results are summarised as follows:

• NXP002 alone delivers a strong, consistent anti-inflammatory effect as demonstrated by suppression of the release of inflammatory cytokines by over 90% for all cytokines studied; and

• the results further suggest that NXP002 may provide additional efficacy in combination with SoC's, even in patients not responding to SoC therapy alone.

Patents secured to protect the rights in

USA

Japan

Europe

The patents offer the opportunity for worldwide sales and as such the company could tie up a global deal package with potential annual sales of over $1bn made up of eligible patients of

USA 10,000 @ £50k+

Japan 4,000 @ £40k+

Europe 11,000 @ £25k+

Global deal now patents secured potential for hundred of million $ to NFX came

Commercial discussions have been ongoing for some time, due to the amount of monies at stake and the number of different options to be discussed with each interested party- upfront payments and milestones, royalty payments but at a company valuation of £700k with discussions at an advanced stage now looks an opportunity to buy or add

£700k mkt cap

Listed for £12m

3.71p - risked global value based on annual sales at 10% LOA and 50%operating margin / £52.8m

This just for NPX002 and I think we all know they are talking with AZ for NPX004

The inhalation route is a well-known strategy for the treatment of lung diseases to yield greater efficacy and reduce systemic, off-target side-effects compared to oral treatment. Discontinuation of treatment in IPF and PPF patients is currently an issue in the treatment of these diseases with discontinuation rates for current SoCs up to 80% in certain patient groups due to their debilitating systemic side-effects. Effective inhalation therapies offer the potential to overcome these limitations of oral therapies.

NXP002 as a potential treatment for IPF, is a likely candidate for Orphan Drug Designation, which could provide additional product protection against potential future competitors in addition to product development advantages. Draft application submitted and initial Meeting expected this month Jan 25.

The positioning of NXP002 as an inhaled treatment for IPF and PPF could be either as added to SoC treatments or administered as a monotherapy for patients non-responsive to SoCs and those declining these therapies due to side effects which impact quality of life.

The Group's pre-clinical inhalation development strategy has significantly progressed NXP002 towards validation of its Target Product Profile ("TPP") demonstrating:

• NXP002 can be delivered in-vivo by a range of nebulisers at the optimum particle size for delivery to the deep lung;

• high doses appear to be well-tolerated; and

• an in-vivo inhalation dose response was observed for inflammatory and fibrotic biomarkers that is consistent with ex-vivo human IPF tissue studies to date.

The Group conducted studies in a new iteration of a 3D human IPF lung tissue using a disease and species relevant model that has been advanced to significantly reduce output variability. The results from these studies of NXP002 alone and in combination with current SoCs, can be summarised as follows:

• NXP002 is well tolerated in ex-vivo human lung tissue with no signs of toxicity events;

• NXP002 alone delivers a strong, consistent anti-fibrotic and anti-inflammatory effect as demonstrated by modulation of the release of multiple biomarkers of fibrosis and inflammation;

• both high and low concentrations of NXP002 show an additive anti-fibrotic and anti-inflammatory effect to SoC;

• in particular, the higher concentrations of NXP002 with SoC's deliver a near complete ablation of fibrosis biomarker release, yet at lower concentrations than have been seen in other preclinical models to date; and

• the clear, pronounced additive benefit of NXP002 on top of SoCs observed suggests that NXP002 may provide additional efficacy, even in patients responding to SoC therapy.